Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KYMR
SELLKymera Therapeutics, Inc. · Healthcare · United States · $9.1B · Avg Vol: $119M/d
COMPANY DESCRIPTION
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics that selectively degrade disease-causing proteins using its proprietary targeted protein degradation platform. Its competitive moat is its specialized DELigase™ platform and expertise in molecular glue degraders, targeting previously 'undruggable' proteins across oncology and immunology. Kymera is a cutting-edge biotechnology firm at the forefront of a promising new drug discovery modality.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 46.8M | 78.6M | 47.1M | 39.2M | -5.7% | 51.5M | 85.4M | 41.0M | 2.3% |
| EPS | -2.09 | -2.87 | -2.52 | -2.98 | -3.69 | — | -3.43 | -3.51 | -4.35 | — |
| Shares | — | 55.0M | 55.6M | 64.9M | 81.3M | +47.8% | 82.3M | — | — | — |
| Debt | — | 17.3M | 84.7M | 87.8M | 82.3M | 68.0% | 80.5M | — | — | — |
| Equity | — | 490.2M | 395.0M | 835.6M | 1.6B | 47.7% | — | — | — | — |
| Op CF | — | -153.1M | -102.8M | -194.5M | -232.9M | — | -242.6M | — | — | — |
| Inv CF | — | 20.5M | 139.9M | -404.1M | -521.1M | — | — | — | — | — |
| Fin CF | — | 153.0M | 4.2M | 608.9M | 990.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KYMR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc.(you) | $9.1B | 25 | SELL |
| CYTK | Cytokinetics, Incorporated | $11.0B | 26 | SELL |
| PCVX | Vaxcyte, Inc. | $7.9B | 27 | SELL |
| PRAX | Praxis Precision Medicines, Inc. | $9.1B | 29 | SELL |
| IBRX | ImmunityBio, Inc. | $7.4B | 26 | SELL |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.9B | 30 | SELL |
| COGT | Cogent Biosciences, Inc. | $6.8B | 25 | SELL |
| NUVL | Nuvalent, Inc. | $9.8B | 30 | SELL |
| SYRE | Spyre Therapeutics, Inc. | $8.9B | 32 | SELL |
| CGON | CG Oncology, Inc. | $6.1B | 24 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%